DCPH - Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday? | Benzinga
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion.
Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities.
In addition to QINLOCK – Deciphera’s ...